Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oculis Holding AG (OCS) Capital Expenditures (2022 - 2026)

Quarterly Capital Expenditures rose 38.18% to -$8939.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$363691.2 through Mar 2026, down 38.33% year-over-year, with the annual reading at -$376602.1 for FY2025, 43.44% down from the prior year.

Oculis Holding AG's Capital Expenditures history spans 5 years, with the latest figure at -$8939.0 for Q1 2026.

  • Capital Expenditures came in at -$8939.0 for Q1 2026, up from -$47544.5 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of -$5636.8 in Q4 2023 to a low of -$177747.9 in Q3 2024.
  • The 5-year median for Capital Expenditures is -$31063.7 (2022), against an average of -$63064.4.
  • Year-over-year, Capital Expenditures surged 61.21% in 2023 and then crashed 1054.33% in 2024.
  • Oculis Holding AG's Capital Expenditures stood at -$14532.3 in 2022, then soared by 61.21% to -$5636.8 in 2023, then plummeted by 1054.33% to -$65066.7 in 2024, then increased by 26.93% to -$47544.5 in 2025, then skyrocketed by 81.2% to -$8939.0 in 2026.
  • Per Business Quant, the three most recent readings for OCS's Capital Expenditures are -$8939.0 (Q1 2026), -$47544.5 (Q4 2025), and -$155013.6 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 133.40 Mn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 230.60 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 21.83 Mn
10 Oculis Holding AG 24.51 Bn 24.21 Bn - -8,939.03

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -8,939.03
Mar 31, 2026 -8,939.03
Dec 31, 2025 -47,544.45
Dec 31, 2025 -47,544.45
Sep 30, 2025 -155,013.58
Sep 30, 2025 -155,013.58
Jun 30, 2025 -152,194.17
Jun 30, 2025 -152,194.17
Mar 31, 2025 -14,459.26
Mar 31, 2025 -14,459.26
Dec 31, 2024 -65,066.75
Dec 31, 2024 -65,066.75
Sep 30, 2024 -177,747.92
Sep 30, 2024 -177,747.92
Dec 31, 2023 -5,636.77
Dec 31, 2023 -5,636.77
Sep 30, 2023 -21,510.90
Sep 30, 2023 -21,510.90
Dec 31, 2022 -14,532.31
Dec 31, 2022 -14,532.31
Sep 30, 2022 -31,063.70
Sep 30, 2022 -31,063.70